The $2 million NIH grant provides significant financial support for TransCode Therapeutics' clinical evaluation of its lead candidate. This funding can accelerate their R&D efforts, potentially leading to successful clinical outcomes and increased future revenues. The news is highly relevant and important for investors as it directly impacts the company's financial and operational capabilities.